Amarin has signaled its willingness to compete “very aggressively” with a US authorized generic version of its Vascepa (icosapent ethyl) if and when it decides to launch. The comments from management came as the firm announced a restructuring and a new CEO, in the wake of increasing competitive pressure from generics (see sidebar).
Aaron Berg – who has served as interim president and CEO since April 2023 – has now been replaced by Patrick Holt as president and CEO, with Berg due to remain with Amarin “in a senior leadership role
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?